JP3188583B2 - Magnesium supplements and their use - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION This invention is, and magnesium supplementation material
More specifically, the present invention relates to a magnesium supplement having excellent absorbability and an effect of improving various pathological symptoms caused by magnesium deficiency, and its use .

[0002]

BACKGROUND OF THE INVENTION Magnesium is a mineral that is involved in many enzymatic reactions in vivo. In addition, magnesium is abundant in bone in a living body, and its deficiency causes osteoporosis and osteomalacia. In addition, magnesium is involved in the biodistribution of calcium, the same divalent ion, and its deficiency causes ectopic calcifications such as kidney stones. In addition, magnesium deficiency is considered to contribute to diseases such as diabetes and hypertension.

It has been reported that the administration of magnesium for these diseases has a therapeutic effect. In addition, epidemiological studies suggest that the relative lack of magnesium relative to calcium contributes to ischemic heart disease.
In addition, it has been reported that the intake of magnesium is effective for improving the motor function during training by sports or the like even in healthy people.

Thus, many recent studies have revealed that magnesium plays an important physiological role in vivo. At present, the target daily intake of magnesium in humans is 3 in Japan.
However, it is difficult to achieve this goal in the diet, and the actual dietary survey estimated that the intake was about 200 mg, and the lack of about 100 mg was pointed out and became a problem. I have. Further, the absorption of magnesium is easily affected by other dietary components such as dietary fiber, calcium, and phosphorus, and even if the intake amount is simply increased, it may be effectively absorbed by the living body and not used.

It is an object of the present invention to provide a magnesium supplement excellent in absorbability and a technique for utilizing the same in order to solve such nutritional problems based on the current state of diet. It has been known for a long time that lactose has a calcium absorption promoting effect, and is considered to be one of the causes of the good calcium absorption of milk. Lactose is less digestible than sucrose, and lactose intolerance is a typical example.

The present inventors have found that such an action is not specific to lactose, but an action common to all indigestible carbohydrates and sugar alcohols which are hardly digested by digestive enzymes secreted from the living body. I made a hypothesis that I repeated my research.
As a result, it was found that fructooligosaccharides, which are indigestible oligosaccharides, have a stronger mineral absorption promoting effect than lactose. In addition, the inventors have found that the effect of fructooligosaccharides on promoting mineral absorption is stronger for magnesium than for calcium. This effect is off
After La Kutoorigo sugar reaches the large intestine, undergo fermentation by intestinal bacteria, it is estimated to be due to an organic acid generated at that time.

[0007]

That is, the present invention comprises a magnesium source, a fructooligosaccharide, and a magnesium salt.
Of fructooligosaccharides to magnesium in the source
Ratio containing magnesium supplementation material and the magnesium supplementation material, characterized in that (weight ratio) is 10 to 400 times
Amelioration of magnesium deficiency symptoms characterized by having
Provides a prophylactic agent .

Although the magnesium source used in the present invention is not particularly limited, magnesium carbonate, magnesium chloride and magnesium sulfate can be used as food additives. Natural magnesium sources include seaweeds such as aonori, kelp, and hijiki, which contain high magnesium, seeds such as cacao beans, sesame, soybeans, almonds, peanuts, rice bran, bitter, and other processed foods. Is suitable.

Here, magnesium in a magnesium source
The ratio of fructooligosaccharide to fructo-oligosaccharide is
Rigo sugar is 10 times or more of magnesium, usually 10 to 40
It is desirable to make it 0 times .

An agent for ameliorating or preventing a magnesium deficiency symptom;
The magnesium supplement of the present invention, which can be used as a tablet, can be taken in any form such as granules, capsules, tablets, powders, and liquids, but it goes without saying that it may be taken in a food. No.

[0011]

The present invention will be specifically described below with reference to examples.
They do not limit the invention. Example 1 4-week-old male Sprague-Dawley rats (body weight 100-11)
0 g) was bred for one week with a standard solid sample (MF: manufactured by Oriental Yeast), and then subjected to the test in groups of 7 animals each.
As shown in Table 1, a feed containing no magnesium was used as a control, and a feed containing only magnesium and six kinds of magnesium supplements having different ratios of magnesium and fructooligosaccharide, which is an indigestible oligosaccharide, were added thereto. Rats were fed food for 14 days, and 14 days later,
On the 4th day, a balance test of magnesium was conducted. In addition, redness symptoms of the auricle and occipital region, which are symptoms of magnesium deficiency, were also observed. Distilled water was used as drinking water, and feed and drinking water were freely available.

[0012]

Table 1 Table 1 Test sample composition table (%)

The prepared feed and a part of the collected manure are weighed in a magnetic crucible, ashed in an electric furnace at 550 ° C. for 18 hours, dissolved in 0.1N hydrochloric acid, and the magnesium content is measured by an ion plasma emission spectrometer. (ICP-S50 manufactured by Shimadzu Corporation
00) to determine the content. From the measured values of the magnesium content in the feed and the amount of mineral excreted in manure, the absorption rate and retention rate of magnesium were calculated by the following formulas.

[0014]

(Equation 1)

As shown in Table 2, the number and extent of onset and degree of redness of the auricle and occiput were greater in the group receiving the magnesium supplement of the present invention than in the control group and the group receiving only magnesium. Was not observed in the G and H groups in which the weight of fructooligosaccharides with respect to magnesium was 200 times or more. Further, as shown in Table 3, the magnesium absorption rate and the retention rate of the group supplemented with the magnesium supplement of the present invention (the weight of fructooligosaccharides with respect to magnesium was 10 times or more) as compared with the group supplemented with magnesium alone. The magnesium supplement of the present invention was significantly high (hazard rate of 5% or less), indicating that the magnesium supplement of the present invention was excellent in absorbability and bioavailability, and also highly effective in improving redness symptoms due to magnesium deficiency.

[0016]

Table 2 Effect of magnesium supplement of the present invention on the onset of skin redness -: No redness ±: Almost no redness +: Slight redness ++: Medium redness +++: Severe redness ( ^* : Significant difference at risk rate of 5% or less)

[0017]

Table 3 Effect of magnesium supplement of the present invention on magnesium absorption rate and retention rate Mean ± standard deviation (n = 7) ( ^* : significant difference is less than 5% risk level)

Example 2 Male 4-year-old Sprague-Dawley rats (body weight 100-11)
0 g) was bred for one week with a standard solid sample (MF: manufactured by Oriental Yeast), and each group was composed of 6 animals, and subjected to the test.
As shown in Table 4, a feed containing only magnesium and a feed not containing magnesium was used as a control, and
Rats receive a diet supplemented with various magnesium supplements
They were ingested for 4 days. Distilled water was used as drinking water, and feed and drinking water were freely taken. At the end of the test, the abdomen was opened under ether anesthesia, sacrificed by whole blood sampling from the inferior vena cava, and the right and left kidneys were removed. After measuring the weight of the removed kidney,
Weighed in a magnetic crucible, ashed in an electric furnace at 550 ° C. for 18 hours, dissolved in 0.1N hydrochloric acid, and calcium ion-plasma emission spectrometer (ICP-S5000 manufactured by Shimadzu Corporation)
Was used to determine the content.

[0019]

Table 4 Test sample composition table (%)

As shown in Table 5, the group receiving the magnesium supplement of the present invention had lower renal calcium content and suppressed the onset of renal calculi, as compared with the control group receiving only magnesium alone, as shown in Table 5. Kidney weight was also significantly lighter and there was no kidney enlargement. This confirms that the magnesium supplement of the present invention has an effect of preventing the onset of kidney stones due to magnesium deficiency.

[0021]

Table 5 Effect of magnesium supplement of the present invention on kidney Mean ± standard deviation (n = 6) ( ^* : Significant difference at 5% risk level or less)

Example 3 Four-week-old Sprague-Dawley male rats (body weight 100-11)
0 g) was bred for one week in a standard solid sample (MF: manufactured by Oriental Yeast), and then each group consisted of 7 animals, which were subjected to the test.
As shown in Table 6, a diet containing no magnesium and a diet containing only magnesium and a diet supplemented with lactose were used as controls, and rats were fed a diet supplemented with the magnesium supplement of the present invention for 14 days. Four days from the 10th day to the 14th day, a balance test of magnesium was conducted.
Distilled water was used as drinking water, and feed and drinking water were freely available. Analysis of the prepared feed, collected feces, and calculation of the magnesium absorption rate were performed in the same manner as in Example 1.

[0023]

Table 6 Test sample composition table (%)

The results show that, as shown in Table 7, the magnesium absorption rate of the group receiving the magnesium supplement of the present invention was the same as that of the control group receiving only the diet supplemented with magnesium alone and the control group receiving the diet supplemented with lactose. It showed a significantly high value (risk rate: 5% or less) as compared with both control groups, and it was confirmed that the magnesium supplement of the present invention had excellent absorbability.

[0025]

Table 7 Table 7 Magnesium absorption rate of magnesium supplement of the present invention Mean ± standard deviation (n = 7) ( ^* : significant difference is less than 5% risk level)

Example 4 Male 4-year-old Sprague-Dawley rats (body weight 100-11)
0 g) was bred for one week in a standard solid sample (MF: manufactured by Oriental Yeast), and then each group consisted of 7 animals, which were subjected to the test.
As shown in Table 8, two types of magnesium supplements according to the present invention were added to a diet containing no magnesium and a diet to which only magnesium was added and a diet to which twice the amount of magnesium was further added as a control. Rats were ingested with the diet for 28 days, and a magnesium balance test was performed for 4 days from day 24 to day 28. At the end of the exam,
The rats were sacrificed and dissected, and the femurs were excised. Distilled water was used as drinking water, and feed and drinking water were freely taken. Analysis of the prepared feed, collected feces, and calculation of the magnesium absorption rate were performed in the same manner as in Example 1.
The analysis of calcium in the femur was performed in the same manner as in Example 2.

[0027]

[Table 8] Table 8 Test sample composition table (%)

The results show that, as shown in Table 9, the magnesium absorption rate of the group ingesting the magnesium supplement of the present invention was significantly (risk rate 5%) as compared with the control group ingesting the diet containing only magnesium alone. The following shows high values, and it was confirmed that the magnesium supplement of the present invention had excellent absorbability. In the group D to which the magnesium supplement of the present invention was added, the amount of absorption was larger than that of the group ingesting the feed containing twice the amount of magnesium. It was confirmed that it could be obtained.

[0029]

Table 9 Magnesium absorption rate and absorption amount of magnesium supplement of the present invention Mean ± standard deviation (n = 7) ( ^* : significant difference is less than 5% risk level)

Further, as shown in Table 10, the content of calcium in bone was also significantly increased, and a decrease in ossification due to magnesium deficiency was prevented.

[0031]

Table 10 Effect of magnesium supplement of the present invention on femoral calcium content Mean ± standard deviation (n = 7) ( ^* : significantly higher than 5% risk level)

[0032]

EFFECT OF THE INVENTION Magnesium deficiency is a risk factor for diseases such as kidney stones, diabetes, hypertension, and ischemic heart disease. Magnesium intake can improve the motor function of healthy people during training by sports and the like. It is valid. Although the target daily intake of magnesium in humans is 300 mg, it is difficult to achieve this target in an actual diet, and at present, 100 m
Insufficient intake of about g has been pointed out. In addition, magnesium absorption is susceptible to other dietary components, and simply increasing the intake may not be effectively used by the living body. Ingestion of the magnesium supplement of the present invention, which is excellent in magnesium absorbability and bioavailability, can prevent and treat many diseases caused by insufficient magnesium intake.

Continued on the front page (51) Int.Cl. ⁷ Identification code FI A61P 13/12 A61P 13/12 19/10 19/10 29/00 29/00 (72) Inventor Toshio Takizawa 5-3 Chiyoda, Sakado-shi, Saitama (1) Meiji Seika Co., Ltd. Biological Science Laboratory (56) References JP-A-2-212 (JP, A) JP-A-60-72817 (JP, A) US Patent 5002780 (US, A) Congr. Int. Techno l. Pharm. , 5th, Vol. 1, (1989) p. 476-481 Journal of the Japanese Society of Nutrition and Food Science, Vol. 44, No. 4, (1991) pp. 287-291 (58) Fields investigated (Int. Cl. ⁷ , DB name) A61K 33/06 A23L 1/304 A23L 1/308 A61K 47/36 A61P 3/02 A61P 13/12 A61P 19/10 A61P 29/00 CA (STN) EMBASE (STN) MEDLINE (STN)

Claims (5)

(57) [Claims] 1. A magnesium source and fructooligosaccharide
Containing magnesium and magnesium
When the blending ratio (weight ratio) of ctooligosaccharide is 10 to 400 times
A magnesium supplement characterized by the fact that there is . 2. A magnesium supplement as claimed in claim 1.
Amelioration of magnesium deficiency symptoms characterized by having
Is a prophylactic agent . 3. The magnesium deficiency symptom is redness.
The improvement or prevention agent according to claim 2 . 4. The magnesium deficiency symptom is kidney stones.
The improving or preventing agent according to claim 2 . 5. The magnesium deficiency symptom is decreased ossification.
3. The improving or preventing agent according to claim 2 .